Chinese biopharmaceutical company RemeGen Co., Ltd. (SHA:688331, HKG:09995) announced on Friday that it has received clearance from the United States Food and Drug Administration to initiate Phase II clinical trials for its bispecific antibody RC148.
RC148 is a novel bispecific antibody designed for the treatment of multiple advanced malignant solid tumours targeting both PD-1 and VEGF. It was developed using RemeGen's proprietary bispecific antibody technology platform.
Clinical trials for RC148, both as a monotherapy and in combination treatments, are currently ongoing in China.
FDA approval to proceed with US trials represents a major milestone in RC148's global clinical development strategy.
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
PainReform acquires majority stake in LayerBio to advance dropless cataract surgery therapy
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial
Novartis reports positive Phase III trial results for ianalumab in immune thrombocytopenia
Viatris' generic iron sucrose injection gains US FDA approval
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100 in treating suicidal depression
IO Biotech reports Phase 3 trial results for Cylembio plus pembrolizumab in advanced melanoma
Novartis reports positive Phase III results for ianalumab in Sjögren's disease